SPY продолжает расти на премаркете
Ближайший уровень поддержки по SPY – 190.50 уровень сопротивления – 192.25
SHLD продажа от 35
TSO продажа от 66
SOXL покупка выше 85
AAP смотрим на продажу
Gapping up/down: ILMN +9%, HOG +8%, TXN and AAPL +2% after earnings, PANW +1.5% after target raise; HAL +1% after upgrade; RMBS, -7%, ARMH -6%, KO -3% and MCD -2% after earnings, IBM -1% after dg Price: null Change: null
Gapping up
In reaction to strong earnings/guidance: LXK +11%, ILMN +8.8%, HOG +7.8%, WERN +4.6%, CE +4.1%, CSL +3.7%, HLX +3.6%, WAT +2.5%, TXN +2.4%, AAPL +2.3%, AOS +2.3%, MBCN +2.2%, UTX +2%, STLD +1.9%, CDNS +1.1%, TRV +1.1%, ELS +0.9%, KMB +0.9%, CP +0.8%
M&A news: ACT +1.5% (Actavis and Sanofi (SNY) may be among bidders for Omega Pharma, according to reports).
Select EU financial related names showing strength: LYG +2.7%, RBS +2.5%, ING +2.3%, DB +0.8%.
Select metals/mining stocks trading higher: X 2.3%, MT 1.8%, AG 1.5%, GFI -0.5%.
Select oil/gas related names showing strength: STO +2.7%, SDRL +2.6%, BP +1.6%
Other news: NEON +22% (signs technology development agreement with global tier one printer OEM ), SGYP +13.1% (presents positive Phase 2b study results for Plecanatide in patients with irritable bowel syndrome), SCOK +5.6% (cont momentum), NXPI +2.6% (following TXN / AAPL results), GSAT +2.6% (co reiterated value of its spectrum assets; believes Kerrisdale continues to 'distort facts in attempt to undermine the benefits of TLPS'), TKMR +2.4% (cont momentum), CRUS +2.2% (following AAPL results), ABBV +2% (announced new $5 bln stock repurchase and increases dividend), BRCM +1.9% (following TXN results), RCL +1.9% (cont strength following yday's advance), TSL +1.7% (still checking), RFMD +1.5% (following AAPL results — component supplier), ACT +1.5% (Actavis and Sanofi (SNY) may be among bidders for Omega Pharma, according to reports), MU +1.4% (following TXN results), SUNE +1.4% (still checking), CCL +1.3% (cont strength following yday's advance), MGM +1.3% (still checking), MPW +1% (announced more than $1 billion in new real estate investments; expected to be accretive to normalized FFO by $0.09 — $0.12 per share), JEC +1% (awarded remediation task order for Eielson Air Force Base, Alaska worth ~$18.7 mln)
Analyst comments: POST +3.2% (upgraded to Buy from Neutral at Goldman), KITE +1.7% (target raised to $45 at Stifel), PANW +1.5% (target raised to $115 at Oppenheimer), COG +1.2% (upgraded to Outperform from Mkt Perform at Bernstein), HAL +1.2% (upgraded to Buy from Neutral at Guggenheim), EOG +0.5% (upgraded to Buy from Neutral at Guggenheim)
Gapping down
In reaction to disappointing earnings/guidance: GLF -8%, RMBS -6.9%, KALU -6.8%, UCTT -6.3%, ARMH -5.9%, APOL -5.4%, CMG -5.2%, XRS -3.3%, KO -3.1%, PKG -2.5%, CYS -1.6%, RCII -1.6%, LMT -1.6%, MCD -1.5%, IHG -1%, ZION -0.9%, BRO -0.9%, VZ -0.8%,.
Select Brazil related names showing weakness: OIBR -8.2%, PBR -7.7% SID -3.5%, VIV -2.8%, ELP -2.5%, GGB -2.2%, SBS -2.1%, VALE -1.7%, ABEV -1.4%.
Other news: RNO -42.8% (announces Q3 distribution of $0.05 per unit, lowered from previous quarter distribution of $0.445 per unit; co redoubling its cost cutting efforts due to weak coal markets), IBIO -20.2% (cont volatility), CVM -17.6% (announces proposed public offering of Common Stock; terms not disclosed), OMER -15% (provides update on PDE10 inhibitor program; enrollment in Huntington's Trial suspended pending further assessment of preclinical data), PT -8.3% (still checking, but Oi SA announces liquidation of assets will have no impact on the business combination with Portugal Telecom), LAKE -2.9% (cont weakness), TLLP -2% (prices upsized public offering of 20 mln common units at $57.47 per unit), SPLS -1.8% (spokesman has indicated company is investigating possible data breach, according to reports), ENTA -1.7% (provides update on its collaboration agreement with AbbVie (ABBV); co-development option on next-generation Protease Inhibitor ABT-493 Not Exercised, net sales allocations for ABT-450-containing regimens finalized), PHG -1.7% (cont weakness), REN -1.4% (provides operation update: Three Permian Basin horizontal wells averaged 1,300 Boe per day on peak 24-hour IP tests), GSK -1.3% (still checking), TRN -1.2% (late sell-off on guardrails ruling; confirms $175 mln in damages at jury trial)
Analyst comments: PHG -1.7% (downgraded to Neutral from Buy at UBS), IBM -0.7% (downgraded to Hold from Buy at Evercore; target lowered to $170 at RBC Capital Mkts), IRC -0.6% (downgraded to Underperform from Neutral at BofA/Merrill), ED -0.4% (downgraded to Underweight at Morgan Stanley)
Оригинал статьи: gtstocks.com/analytics-21-10-2014.html
SHLD продажа от 35
TSO продажа от 66
SOXL покупка выше 85
AAP смотрим на продажу
Gapping up/down: ILMN +9%, HOG +8%, TXN and AAPL +2% after earnings, PANW +1.5% after target raise; HAL +1% after upgrade; RMBS, -7%, ARMH -6%, KO -3% and MCD -2% after earnings, IBM -1% after dg Price: null Change: null
Gapping up
In reaction to strong earnings/guidance: LXK +11%, ILMN +8.8%, HOG +7.8%, WERN +4.6%, CE +4.1%, CSL +3.7%, HLX +3.6%, WAT +2.5%, TXN +2.4%, AAPL +2.3%, AOS +2.3%, MBCN +2.2%, UTX +2%, STLD +1.9%, CDNS +1.1%, TRV +1.1%, ELS +0.9%, KMB +0.9%, CP +0.8%
M&A news: ACT +1.5% (Actavis and Sanofi (SNY) may be among bidders for Omega Pharma, according to reports).
Select EU financial related names showing strength: LYG +2.7%, RBS +2.5%, ING +2.3%, DB +0.8%.
Select metals/mining stocks trading higher: X 2.3%, MT 1.8%, AG 1.5%, GFI -0.5%.
Select oil/gas related names showing strength: STO +2.7%, SDRL +2.6%, BP +1.6%
Other news: NEON +22% (signs technology development agreement with global tier one printer OEM ), SGYP +13.1% (presents positive Phase 2b study results for Plecanatide in patients with irritable bowel syndrome), SCOK +5.6% (cont momentum), NXPI +2.6% (following TXN / AAPL results), GSAT +2.6% (co reiterated value of its spectrum assets; believes Kerrisdale continues to 'distort facts in attempt to undermine the benefits of TLPS'), TKMR +2.4% (cont momentum), CRUS +2.2% (following AAPL results), ABBV +2% (announced new $5 bln stock repurchase and increases dividend), BRCM +1.9% (following TXN results), RCL +1.9% (cont strength following yday's advance), TSL +1.7% (still checking), RFMD +1.5% (following AAPL results — component supplier), ACT +1.5% (Actavis and Sanofi (SNY) may be among bidders for Omega Pharma, according to reports), MU +1.4% (following TXN results), SUNE +1.4% (still checking), CCL +1.3% (cont strength following yday's advance), MGM +1.3% (still checking), MPW +1% (announced more than $1 billion in new real estate investments; expected to be accretive to normalized FFO by $0.09 — $0.12 per share), JEC +1% (awarded remediation task order for Eielson Air Force Base, Alaska worth ~$18.7 mln)
Analyst comments: POST +3.2% (upgraded to Buy from Neutral at Goldman), KITE +1.7% (target raised to $45 at Stifel), PANW +1.5% (target raised to $115 at Oppenheimer), COG +1.2% (upgraded to Outperform from Mkt Perform at Bernstein), HAL +1.2% (upgraded to Buy from Neutral at Guggenheim), EOG +0.5% (upgraded to Buy from Neutral at Guggenheim)
Gapping down
In reaction to disappointing earnings/guidance: GLF -8%, RMBS -6.9%, KALU -6.8%, UCTT -6.3%, ARMH -5.9%, APOL -5.4%, CMG -5.2%, XRS -3.3%, KO -3.1%, PKG -2.5%, CYS -1.6%, RCII -1.6%, LMT -1.6%, MCD -1.5%, IHG -1%, ZION -0.9%, BRO -0.9%, VZ -0.8%,.
Select Brazil related names showing weakness: OIBR -8.2%, PBR -7.7% SID -3.5%, VIV -2.8%, ELP -2.5%, GGB -2.2%, SBS -2.1%, VALE -1.7%, ABEV -1.4%.
Other news: RNO -42.8% (announces Q3 distribution of $0.05 per unit, lowered from previous quarter distribution of $0.445 per unit; co redoubling its cost cutting efforts due to weak coal markets), IBIO -20.2% (cont volatility), CVM -17.6% (announces proposed public offering of Common Stock; terms not disclosed), OMER -15% (provides update on PDE10 inhibitor program; enrollment in Huntington's Trial suspended pending further assessment of preclinical data), PT -8.3% (still checking, but Oi SA announces liquidation of assets will have no impact on the business combination with Portugal Telecom), LAKE -2.9% (cont weakness), TLLP -2% (prices upsized public offering of 20 mln common units at $57.47 per unit), SPLS -1.8% (spokesman has indicated company is investigating possible data breach, according to reports), ENTA -1.7% (provides update on its collaboration agreement with AbbVie (ABBV); co-development option on next-generation Protease Inhibitor ABT-493 Not Exercised, net sales allocations for ABT-450-containing regimens finalized), PHG -1.7% (cont weakness), REN -1.4% (provides operation update: Three Permian Basin horizontal wells averaged 1,300 Boe per day on peak 24-hour IP tests), GSK -1.3% (still checking), TRN -1.2% (late sell-off on guardrails ruling; confirms $175 mln in damages at jury trial)
Analyst comments: PHG -1.7% (downgraded to Neutral from Buy at UBS), IBM -0.7% (downgraded to Hold from Buy at Evercore; target lowered to $170 at RBC Capital Mkts), IRC -0.6% (downgraded to Underperform from Neutral at BofA/Merrill), ED -0.4% (downgraded to Underweight at Morgan Stanley)
Оригинал статьи: gtstocks.com/analytics-21-10-2014.html
0 комментариев